PDF(Pubmed)
Abstract：
UNASSIGNED: We performed a systematic review and meta-analysis to further explore the impact of the addition of immunotherapy to gemcitabine-cisplatin as first-line treatment for advanced biliary tract cancer (BTC) patients.
UNASSIGNED: Literature research was performed, and hazard ratio values and 95% confidence intervals were calculated. Heterogeneity among studies was assessed using the tau-squared estimator ( τ 2 ) . The total Cochrane Q test (Q) was also assessed. The overall survival rate, objective response rate, and progression-free survival in the selected studies were assessed.
UNASSIGNED: A total of 1,754 participants were included. Heterogeneity among the studies selected was found to be non-significant (p = 0.78; tau2 = 0, I2 = 0%). The model estimation results and the forest plot suggested that the test for the overall effect was significant (Z = -3.51; p< 0.01).
UNASSIGNED: The results of the current meta-analysis further confirm the role of immune checkpoint inhibitors plus gemcitabine-cisplatin as the new standard first-line treatment for advanced BTC patients.
UNASSIGNED: https://www.crd.york.ac.uk/prospero, identifier CRD42023488095.
UNASSIGNED: Literature research was performed, and hazard ratio values and 95% confidence intervals were calculated. Heterogeneity among studies was assessed using the tau-squared estimator ( τ 2 ) . The total Cochrane Q test (Q) was also assessed. The overall survival rate, objective response rate, and progression-free survival in the selected studies were assessed.
UNASSIGNED: A total of 1,754 participants were included. Heterogeneity among the studies selected was found to be non-significant (p = 0.78; tau2 = 0, I2 = 0%). The model estimation results and the forest plot suggested that the test for the overall effect was significant (Z = -3.51; p< 0.01).
UNASSIGNED: The results of the current meta-analysis further confirm the role of immune checkpoint inhibitors plus gemcitabine-cisplatin as the new standard first-line treatment for advanced BTC patients.
UNASSIGNED: https://www.crd.york.ac.uk/prospero, identifier CRD42023488095.
摘要：
■我们进行了系统评价和荟萃分析，以进一步探讨吉西他滨-顺铂作为晚期胆道癌（BTC）患者一线治疗的疗效。
■进行了文献研究，计算风险比值和95%置信区间.使用tau平方估计器(τ2)评估研究之间的异质性。还评估了总CochraneQ测试(Q)。总生存率,客观反应率，对所选研究中的无进展生存期进行了评估.
■总共包括1,754名参与者。发现所选研究之间的异质性是不显著的(p=0.78;tau2=0,I2=0%)。模型估计结果和森林地块表明，总体效果的检验是显着的（Z=-3.51；p<0.01）。
■当前荟萃分析的结果进一步证实了免疫检查点抑制剂加吉西他滨-顺铂作为晚期BTC患者的新标准一线治疗的作用。
■https://www.crd.约克。AC.英国/普劳里,标识符CRD42023488095。
■进行了文献研究，计算风险比值和95%置信区间.使用tau平方估计器(τ2)评估研究之间的异质性。还评估了总CochraneQ测试(Q)。总生存率,客观反应率，对所选研究中的无进展生存期进行了评估.
■总共包括1,754名参与者。发现所选研究之间的异质性是不显著的(p=0.78;tau2=0,I2=0%)。模型估计结果和森林地块表明，总体效果的检验是显着的（Z=-3.51；p<0.01）。
■当前荟萃分析的结果进一步证实了免疫检查点抑制剂加吉西他滨-顺铂作为晚期BTC患者的新标准一线治疗的作用。
■https://www.crd.约克。AC.英国/普劳里,标识符CRD42023488095。
